CD3-Binding Recombinant Antibodies with Optimized CDR Sequences

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing antibodies targeting CD3 often lack optimal binding affinity and specificity, which can limit their effectiveness in therapeutic applications.

Innovation Solution

Development of recombinant antibodies with specific CD3 binding domains comprising defined CDR sequences in immunoglobulin light and heavy chains, enhancing binding affinity and specificity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing antibodies are used to target CD3, then therapeutic applications can be pursued, but binding affinity and specificity are insufficient

Engineering Contradiction:

Improvebinding affinityVSAvoidantibody development complexity

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent applies parameter changes by systematically mutating amino acid residues in the CDR3 region of the antibody binding domain to optimize binding affinity. Specific residues were mutated to create variants with improved pharmacological properties, directly addressing the insufficiency of binding affinity in existing antibodies.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses copying by creating recombinant antibodies that replicate and refine the binding domain structure of natural antibodies. The recombinant antibodies are constructed with defined CDR sequences that copy the functional elements of natural anti-CD3 antibodies while incorporating optimized mutations.

Inventive Principle:

Principle #26Copying

2Reliability

If existing antibodies are used to target CD3, then therapeutic applications can be pursued, but binding specificity is insufficient

Engineering Contradiction:

Improvebinding specificityVSAvoidantibody structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies local quality by focusing optimization efforts specifically on the CDR3 region of the antibody binding domain, where the most critical amino acid residues for specificity are located. By concentrating mutations and optimizations in this localized region rather than the entire antibody structure, the patent achieves improved specificity without proportionally increasing overall structural complexity.

Inventive Principle:

Principle #3Local quality

3Reliability

If recombinant antibodies with optimized CDR sequences are developed, then binding affinity and specificity are enhanced, but development time and complexity increase

Engineering Contradiction:

Improvebinding affinityVSAvoidantibody development time

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent applies preliminary action by pre-defining the optimal CDR sequences through in silico modeling and computational analysis before actual antibody production. The binding domain is designed with predetermined mutations that are known to improve affinity and specificity, allowing the recombinant antibodies to be produced more quickly without requiring extensive trial-and-error optimization.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20260049137A1Optimized antibodies targeting CD3 and uses thereof

Publication Date: 2026.02.19 JANUX THERAPEUTICS INC

AI summary

Disclosed herein are recombinant antibodies or antigen binding fragments thereof that comprise a CD3 binding domain that has been optimized via alanine scanning mutagenesis. In some embodiments, the recombinant antibodies or antigen binding fragments thereof further comprise an antigen binding domain.